Previous 10 | Next 10 |
CAMBRIDGE, Mass., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the pricing of an underwritten offering and a private placement, with combined gross proceeds of approximately $115.8 million. In the underwritten...
Trem-cel (formerly VOR33) successfully manufactured and engrafted normally Blood counts successfully maintained following post-transplant treatment with Mylotarg Conference call scheduled for today, December 7 at 8:00am ET CAMBRIDGE, Mass., Dec. 07, 2022 (GLO...
The following slide deck was published by Vor Biopharma Inc. in conjunction with this event. For further details see: Vor Biopharma (VOR) Investor Presentation -Slideshow
Vor Biopharma press release ( NASDAQ: VOR ): Q3 GAAP EPS of -$0.63 misses by $0.03 . Cash, cash equivalents and investments were $136.1 million as of September 30, 2022, which is anticipated to fund operations into the first quarter of 2024. For further details s...
Initial clinical data for VOR33 on track for Q4 2022 Eyal C. Attar, M.D. appointed as Chief Medical Officer Initiated in-house clinical manufacturing at Cambridge, MA headquarters CAMBRIDGE, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a cl...
Vor Bio ( NASDAQ: VOR ) appoints more than 20 years of demonstrated clinical experienced Eyal C. Attar as Chief Medical Officer. Dr. Attar most recently served as senior vice president and CMO for Aprea Therapeutics. For further details see: V...
CAMBRIDGE, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that Eyal C. Attar, M.D., has joined Vor Bio as Chief Medical Officer (CMO). Dr. Attar brings more than 20 years of demonstrated clinical experien...
-Multiplex deletion of myeloid antigens CD33 and CLL-1 or CD33 and CD123 in human hematopoietic stem cells resulted in long-term engraftment and persistence of editing -Data presented at European Society of Gene & Cell Therapy (ESGCT) Annual Congress CAMBRIDGE, Mass., ...
CAMBRIDGE, Mass., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the opening of its new in-house clinical manufacturing facility in Cambridge, Mass. co-located in the Company’s current headquarters. The ...
Vor Biopharma press release ( NASDAQ: VOR ): Q2 GAAP EPS of -$0.58 beats by $0.08 . Cash, cash equivalents and investments were $151.1 million as of June 30, 2022, which is anticipated to fund operations into the first quarter of 2024. For further details see: ...
News, Short Squeeze, Breakout and More Instantly...
On-track for trem-cel and VCAR33 ALLO clinical updates in the second half of 2024 Trem-cel trial expanded to include patients with myelodysplastic syndromes (MDS); Mylotarg™ dosing has advanced to the third cohort CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWI...
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Fouad Namouni, M.D., to its Board of Directors. Dr. Namouni currently serves as President of Research & Development at Blueprint M...
Trem-cel and VCAR33 ALLO clinical trial data expected in the second half of 2024 VCAR33 ALLO granted Fast Track and Orphan Drug Designation by U.S. Food & Drug Administration Cash runway extends into second half of 2025 CAMBRIDGE, Mass., March...